In vitro susceptibility of nonfermenting Gram-negative rods to meropenem-vaborbactam and delafloxacin. 2023

Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
Service de Biologie Clinique, Hôpital Foch, 92150, Suresnes, France.

Aim: Meropenem-vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators. Results: Meropenem-vaborbactam MIC50 were 4 μg/ml for Achr, 1 μg/ml for B. cepacia, 2 μg/ml for B. cenocepacia and B. multivorans, and 32 μg/ml for Smal. Delafloxacin MIC50 were 4 μg/ml for Achr, 0.25 μg/ml for B. cepacia and B. multivorans, 2 μg/ml for B. cenocepacia, and 0.5 μg/m for Smal. meropenem-vaborbactam MICs were fourfold lower than meropenem for 28.3% Achr, 77.2% B. cepacia, 53.8% B. cenocepacia and 77.2% B. multivorans. Conclusion: Meropenem-vaborbactam and delafloxacin are in vitro active against Bcc and Achr.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D042602 Burkholderia cepacia complex A group of phenotypically similar but genotypically distinct species (genomovars) in the genus BURKHOLDERIA. They are found in water, soil, and the rhizosphere of crop plants. They can act as opportunistic human pathogens and as plant growth promoting and biocontrol agents.
D020615 Stenotrophomonas maltophilia A species of STENOTROPHOMONAS, formerly called Xanthomonas maltophilia, which reduces nitrate. It is a cause of hospital-acquired ocular and lung infections, especially in those patients with cystic fibrosis and those who are immunosuppressed. Xanthomonas maltophilia,Pseudomonas maltophilia

Related Publications

Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
March 2002, Journal of clinical microbiology,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
January 2018, Journal of the American Pharmacists Association : JAPhA,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
October 1978, Canadian journal of microbiology,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
May 2022, Antibiotics (Basel, Switzerland),
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
January 2012, Indian journal of medical microbiology,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
November 1969, Mayo Clinic proceedings,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
May 2023, Journal of chemotherapy (Florence, Italy),
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
December 1977, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
October 2009, Journal of clinical microbiology,
Eric Farfour, and Louise Ruffier d'Epenoux, and Anaëlle Muggeo, and Corentine Alauzet, and Lise Crémet, and Sophie Moussalih, and Antoine Roux, and Sylvie C de Verdière, and Amélie Bosphore, and Stéphane Corvec, and Thomas Guillard, and Marc Vasse
January 2007, Diagnostic microbiology and infectious disease,
Copied contents to your clipboard!